Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Mutations in the gene encoding epidermal growth factor receptor (EGFR) family member HER2 (ERBB2) are common in and drive the growth of “HER2-negative” (not ERBB2-amplified) solid tumors but are rare in primary “HER2-positive” (ERBB2-amplified) breast cancer. We analyzed DNA sequencing data from HER...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Signal
Main Authors: Cocco, Emiliano, Carmona, F. Javier, Razavi, Pedram, Won, Helen H., Cai, Yanyan, Rossi, Valentina, Chan, Carmen, Cownie, James, Soong, Joanne, Toska, Eneda, Shifman, Sophie G, Sarotto, Ivana, Savas, Peter, Wick, Michael J., Papadopoulos, Kyriakos P., Moriarty, Alyssa, Cutler, Richard E., Avogadri-Connors, Francesca, Lalani, Alshad S., Bryce, Richard P., Chandarlapaty, Sarat, Hyman, David M., Solit, David B., Boni, Valentina, Loi, Sherene, Baselga, José, Berger, Michael F., Montemurro, Filippo, Scaltriti, Maurizio
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6498841/
https://ncbi.nlm.nih.gov/pubmed/30301790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.aat9773
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados